Initial Statement of Beneficial Ownership (3)
07 January 2023 - 08:32AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP
OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Balthaser Kevin |
2. Date of Event Requiring Statement
(MM/DD/YYYY)
1/1/2023
|
3. Issuer Name and Ticker or Trading
Symbol Aclaris Therapeutics, Inc. [ACRS] |
(Last)
(First)
(Middle)
C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE
200 |
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
___X___ Officer (give title
below) _____
Other (specify below)
Chief Financial Officer / |
(Street)
WAYNE, PA 19087
(City)
(State)
(Zip)
|
5. If Amendment, Date Original
Filed(MM/DD/YYYY)
|
6. Individual or Joint/Group
Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially
Owned
|
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Common Stock |
700 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying
Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative
Security |
5. Ownership Form of Derivative Security: Direct (D)
or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Employee Stock Option (Right to Buy) |
(1) |
7/4/2027 |
Common Stock |
11200 |
$27.54 |
D |
|
Employee Stock Option (Right to Buy) |
(1) |
1/31/2028 |
Common Stock |
2100 |
$22.09 |
D |
|
Employee Stock Option (Right to Buy) |
(2) |
2/28/2031 |
Common Stock |
15500 |
$24.06 |
D |
|
Employee Stock Option (Right to Buy) |
(3) |
2/29/2032 |
Common Stock |
33400 |
$14.94 |
D |
|
Restricted Stock Units |
(4) |
(4) |
Common Stock |
1475 |
(5) |
D |
|
Restricted Stock Units |
(6) |
(6) |
Common Stock |
3000 |
(5) |
D |
|
Restricted Stock Units |
(7) |
(7) |
Common Stock |
2000 |
(5) |
D |
|
Restricted Stock Units |
(8) |
(8) |
Common Stock |
3300 |
(5) |
D |
|
Restricted Stock Units |
(9) |
(9) |
Common Stock |
9500 |
(5) |
D |
|
Explanation of
Responses: |
(1) |
The shares underlying this
option are fully vested. The expiration date of this option
reported in the table is the day before the tenth anniversary of
the grant date of the option. |
(2) |
The option vests over a
period of four years. 25% of the shares are currently vested with
the remaining 75% vesting annually on March 1, 2023, March 1, 2024
and March 1, 2025, subject to the reporting person's continuous
service with the issuer as of the applicable vesting date. The
expiration date of this option reported in the table is the day
before the tenth anniversary of the grant date of the
option. |
(3) |
The option vests over a
period of four years. 25% of the shares will vest on March 1, 2023,
with the remaining 75% vesting annually thereafter on March 1,
2024, March 1, 2025 and March 1, 2026, subject to the reporting
person's continuous service with the issuer as of the applicable
vesting date. The expiration date of this option reported in the
table is the day before the tenth anniversary of the grant date of
the option. |
(4) |
The shares underlying these
restricted stock units vest on March 1, 2023, subject to the
reporting person's continuous service with the issuer as of the
applicable vesting date. |
(5) |
Each restricted stock unit
represents a contingent right to receive one share of common stock
of the issuer. |
(6) |
The shares underlying these
restricted stock units vest over a period of two years, with
one-half of the shares vesting on each of March 2, 2023 and March
2, 2024, subject to the reporting person's continuous service with
the issuer as of the applicable vesting date. |
(7) |
The shares underlying these
restricted stock units vest over a period of two years, with
one-half of the shares vesting on each of September 1, 2023 and
September 1, 2024, subject to the reporting person's continuous
service with the issuer as of the applicable vesting
date. |
(8) |
The shares underlying these
restricted stock units vest over a period of three years, with
one-third of the shares vesting on each of March 1, 2023, March 1,
2024 and March 1, 2025, subject to the reporting person's
continuous service with the issuer as of the applicable vesting
date. |
(9) |
The shares underlying these
restricted stock units vest in four equal annual installments
beginning on March 1, 2023, subject to the Reporting Person's
continuous service as an officer with the issuer as of the
applicable vesting date. |
Remarks:
Exhibit 24.1 - Power of Attorney |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Balthaser Kevin
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE, PA 19087 |
|
|
Chief Financial Officer |
|
Signatures
|
/s/ Mark Ballantyne, as
Attorney-in-Fact |
|
1/6/2023 |
**Signature of Reporting
Person |
Date |
Reminder: Report on a separate line for each class
of securities beneficially owned directly or
indirectly. |
* |
If the form is filed by more than one
reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions
of facts constitute Federal Criminal Violations. See 18
U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: |
File three copies of this Form, one of
which must be manually signed. If space is insufficient, see
Instruction 6 for procedure. |
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number. |
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Feb 2023 to Mar 2023
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2022 to Mar 2023